Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 8/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5790131 | 0.94 | TRPA1 (0.38) | TRPA1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2957435 | 0.92 | PDE4A (0.48) | TRPA1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6383651 | 0.91 | KMT2A (0.37) | TRPA1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6383655 | 0.86 | PDE4A (0.35) | TRPA1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2957710 | 0.82 | ALDH1A1 (0.57) | ADORA2BKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL5771832 | 0.78 | TRPA1 (0.34) | TRPA1 | |
| SCHEMBL13217673 | 0.76 | PDE4A (0.62) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL2961214 | 0.76 | POLB (0.64) | ADORA2BKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL6380785 | 0.76 | KMT2A (0.52) | ADORA2BKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL6380593 | 0.74 | PDE4A (0.48) | TRPA1PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060094722-A1 | Combination drug | EISAI CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094722-A1 | Combination drug | DPP4, GLP1R, DPP7 | TRPA1 3743/4885PDE4A 39/4885PDE4B 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.